Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 山东金城医药股份有限公司是一家致力于头孢类医药中间体的研发、生产和销售企业.公司的主要产品为AE-活性酯、头孢他啶侧链酸活性酯、头孢克肟侧链酸活性酯、呋喃铵盐.截止2010年底,公司已发展成为国内最大的头孢抗生素侧链中间体生产厂商,公司及下属两家子公司均属国家级高新技术企业.经国家人事部全国博士后管委会批准,公司设立了博士后科研(金城)工作站.此外,公司还先后被认定为国家级火炬计划高新技术企业、山东省认定企业技术中心和山东省头孢类医药中间体工程技术研究中心.公司产品都通过了ISO9001:2000、ISO14001:2004、GB/T28001:2001和ISO10012:2003测量体系和标准化良好行为体系认证.2006年,公司主要产品AE-活性酯被山东省名牌战略推进委员会、山东省质量技术监督局联合评定为"山东名牌产品"。
Main Business 从事医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。
Legal Representative 赵叶青
Top Executives
董事长：赵叶青
副董事长：马钦元,李家全
董事：王辉,张忠政,崔希礼,李家全
独立董事：蔡启孝,李福利,王新宇
Top 5 Shareholder
Shareholder name Nature Holding Date
淄博金城实业投资股份有限公司流通A股20.46%30/09/2024
香港中央结算有限公司流通A股3.36%30/09/2024
赵叶青限售股+流通A股1.88%30/09/2024
赵鸿富流通A股1.74%30/09/2024
青岛富和投资有限公司流通A股1.62%30/09/2024
Company Secretary 朱晓刚
Solicitors 北京市金杜律师事务所
Auditors 大信会计师事务所（特殊普通合伙）
Tel No 0533-5439432
Fax No 0533-5439426;0533-6725431
Website www.jinchengpharm.com
Email jcpc@300233.com
Company Address
Register: 山东省淄博市淄川经济开发区双山路1号
Office: 山东省淄博市淄川经济开发区双山路1号
Listing Date 22/06/2011
Shares Capital
Shares Capital: 383,874,587
Total A Share: 383,874,587
Listed A Share: 369,883,105
Non-tradable A Share: 13,991,482
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.450
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 9.675
Market Capitalization(RMB) 4.694B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.